1.Protective Effect of Ganyu Capsule on Experimental Hepatic Injury
Qiuyan CHAI ; Wenlan HAN ; Wenbing YANG ; Baiqiang LI ; Xianghua SHI ; Jili CUI
Traditional Chinese Drug Research & Clinical Pharmacology 1993;0(02):-
Objective To investigate the protective effect of Ganyu capsule on the experimental hepatic injury in mice and rats.Methods Acute hepatic injury was induced by intraperitoneal injection of 0.1 %CCl4 10mL/kg and D-galactosamine 500 mg/kg in mice;Cirrhosis was induced by 40 %CCl4 adding with variousagents in rats.The biochemical parameters such as serum ALT were examined and the histopathological changes of hepatic tissue was measured.Results Ganyu capsule could obviously inhibit the increase of serum ALT and AST activity and reduce the content of collagen in liver and the deseverity of hepatic fibrosis.Conclusion Ganyu capsule has protective effects on the acute and chronic hepatic injury in mice and rats.
2.A correlative study of CT findings and pulmonary function test in patients with SARS in the recovery phase following hospital discharge
Weihong ZHANG ; Zhengyu JIN ; Yun WANG ; Jixiang LIANG ; Hui YOU ; Liren ZHANG ; Wenbin MOU ; Min PENG ; Yi MA ; Baiqiang CAI ; Zhong WANG ; Wenbing XU ; Taisheng LI ; Wei CUI
Chinese Journal of Radiology 2001;0(05):-
Objective To evaluate the appearance of CT in patients with severe acute respiratory syndrome (SARS) in the recovery phase, and to study the correlation of CT findings with pulmonary function.Methods From June to August in 2003, 100 patient with confirmed SARS accepted examination in our hospital. Among them, 91 patients (39 men, 52 women, mean age 36.4 years, age range 19- 66 years) received CT examination and pulmonary function test on the same day. The interval between SARS onset and the examination ranged from 52 to 125 days (mean 87.4 days). CT appearances of pulmonary parenchymal abnormalities including distribution and extent of involvement were quantitatively analyzed, and four levels on CT scan including the aortic arch, the tracheal carina, the pulmonary venous confluence, and the dome of right diaphragm were selected to score the lesions. The correlation of CT scores with the results of pulmonary function tests was studied.Results Of the 91 cases, 47 patients had normal CT appearance in the recovery phase, whereas the other 44 patients still had parenchymal abnormalities, including residual ground-glass opacification and reticular shadow. CT visual score had correlation with DLco% ( r =-0.618, P
3.Effect of Sequence of Pulmonary Artery and Vein Transection in Thoracoscopic Lobectomy on Efficacy and Safety of Patients with Non-small Cell Lung Cancer: A Systematic Evaluation
Xiangdou BAI ; Ziqiang HONG ; Baiqiang CUI ; Ning YANG ; Xiaoyang HE ; Dacheng JIN ; Yunjiu GOU
Cancer Research on Prevention and Treatment 2023;50(1):69-74
Objective To systematically evaluate the effect of sequence of pulmonary artery and vein transection in thoracoscopic lobectomy on the efficacy and safety of patients with non-small cell lung cancer. Methods PubMed, EMbase, Web of Science, The Cochrane Library, CNKI, Wanfang, VIP and CBM databases were searched for the researches on The post-operative efficacy of pulmonary arteriovenous and pulmonary vein resection sequence in thoracoscopic lobectomy for non-small cell lung cancer. The retrieval time is from the database construction to May 2022. Meta-analysis was performed using RevMan 5.4 software. Results Eight articles were included, including 3 randomized controlled studies and 5 cohort studies, with a total of 1810 patients. Meta-analysis results showed that: The operative time (MD=13.34, 95%
4.Short-Term Efficacy and Postoperative Inflammatory Cytokine Changes in Lung Cancer Treated with Da Vinci Robot-assisted Versus Video-assisted Thoracoscopic Surgery
Ziqiang HONG ; Wenxi GOU ; Yannan SHENG ; Xiangdou BAI ; Baiqiang CUI ; Dacheng JIN ; Yunjiu GOU
Cancer Research on Prevention and Treatment 2023;50(4):378-383
Objective To evaluate the short-term outcomes and postoperative inflammatory cytokine changes in patients with lung cancer treated with robot-assisted thoracoscopic surgery (RATS) versus video-assisted thoracoscopic surgery (VATS). Methods A total of 270 patients with lung cancer treated by minimally invasive surgery were selected for the study, and the surgical procedures were selected according to the patients' economic conditions and preferences. Among them, 132 patients completed the operation through RATS, and 138 patients completed the operation through VATS. The clinical data of the two groups were compared. Results All patients successfully completed radical lung cancer surgery, and no perioperative deaths were reported. Intraoperative bleeding, postoperative drainage time, postoperative hospital stay, number of lymph nodes dissected, and number of lymph nodes dissected groups were more advantageous in the RATS group compared with the VATS group (
5.Clinical Efficacy of Da Vinci Robot-assisted Subxiphoid Versus Lateral Thoracic Approach for Treatment of Anterior Mediastinal Tumors
Ziqiang HONG ; Yannan SHENG ; Xiangdou BAI ; Baiqiang CUI ; Yingjie LU ; Xusheng WU ; Tao CHENG ; Dacheng JIN ; Yunjiu GOU
Cancer Research on Prevention and Treatment 2023;50(6):598-602
Objective To compare the perioperative efficacy and safety of da Vinci robot-assisted thoracoscopic surgery (RATS) for treatment of anterior mediastinal tumors through subxiphoid versus lateral thoracic approaches under the laryngeal mask anesthesia. Methods We retrospectively analyzed the clinical data of 102 patients with anterior-mediastinal tumors treated by RATS under laryngeal mask anesthesia completed by the same operator. Forty-five patients underwent the subxiphoid approach (subxiphoid group), and 57 patients were treated with the lateral thoracic approach (lateral thoracic group). The operating time, intraoperative bleeding, and total postoperative drainage volume in the two groups were compared and analyzed. Results All patients successfully completed resection of the anterior mediastinal tumor without the occurrence of perioperative death. In terms of total postoperative drainage volume, postoperative drainage time, postoperative hospital stay, and VAS pain on postoperative days 2 and 3, the subxiphoid group was more advantages (
6. Role of the m7G methyltransferase METTL1 in tumours
Ziqiang HONG ; Baiqiang CUI ; Xiangdou BAI ; Wenxi GOU ; Ziqiang HONG ; Baiqiang CUI ; Xiangdou BAI ; Dacheng JIN ; Yunjiu GOU
Chinese Journal of Clinical Pharmacology and Therapeutics 2023;28(1):93-100
N7-methylguanosine (m7G) is a common post-transcriptional modification of RNA that plays an important role in RNA processing, metabolism and function and is mainly regulated by the methyltransferase 1 (METTL1) and WD repeat domain 4 (WDR4) complexes. Several studies have shown that the METTL1/WDR4 complex promotes or inhibits the progression of many tumours, including head and neck tumours, lung, liver, colon, bladder and esophageal squamous cancers, which are dependent on m7G methylation modification of tRNA or miRNA. Therefore, METTL1 and m7G modification can be used as biomarkers or potential intervention targets, providing a new direction for early diagnosis and treatment of tumors. This article will mainly discuss the mechanism and corresponding research progress of METTL1 in tumorigenesis through m7G.
7.Prognostic value of platelet-to-lymphocyte ratio in prostate cancer patients:a meta analysis
Chenming GUO ; Xing WANG ; Baiqiang CUI ; Yuhong LUO ; Fenghai ZHOU
Journal of Modern Urology 2023;28(1):50-58
【Objective】 To evaluate the value of platelet-to-lymphocyte ratio (PLR) in the prognosis of prostate cancer. 【Methods】 Relevant studies were searched in CNKI, Wanfang, CBM, VIP, PubMed, Web of Science, Cochrane Library and Embase databases from inception to Dec.2021. The literature was screeded, data were extracted, and the quality was evaluated according to the inclusion and exclusion criteria. A meta-analysis by using the hazard risk (HR) and 95% confidence interval (CI) was adopted to assess the prognostic value of PLR. The data were analyzed with STATA 16.0 software. 【Results】 A total of 10 studies were included, involving 1 802 patients. For patients with high level of PLR, the overall survival (OS) (HR=1.70, 95%CI:1.25-2.30, P=0.001) and disease-free survival (DFS)(HR=1.44, 95%CI:1.15-1.81, P=0.002) were significantly shorter. 【Conclusion】 PLR is an independent risk factor affecting the long-term prognosis of prostate cancer patients. Pretreatment detection of PLR is meaningful in determining the prognosis.
8.Toumai® endoscopic robot-assisted thoracic surgery in three patients
Dacheng JIN ; Baiqiang CUI ; Ning YANG ; Xiaoyang HE ; Yunjiu GOU
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2022;29(04):524-528
Objective To explore the application of Toumai® minimally invasive endoscopic robot in thoracic surgery, and to observe its safety and short-term surgical efficacy. Methods Three patients were enrolled from October to December 2021, including 1 male (69 years) and 2 females (47 years and 22 years). All 3 patients received surgery with Toumai® endoscopic surgical robot, including radical lung cancer surgery in 2 patients and mediastinal tumor resection in 1 patient. Results All 3 patients were successfully operated without conversion to thoracotomy, complication or death. For the male lobectomy patient, the total operation time was 120 min, the intraoperative blood loss was 100 mL, the catheter drainage time was 4 days and the hospital stay time was 5 days. For the female lobectomy patient, the total operation time was 103 min, the intraoperative blood loss was 100 mL, the catheter drainage time was 4 days and the hospital stay time was 5 days. For the female mediastinal tumor patient, the total operation time was 81 min, the intraoperative blood loss was 50 mL, the catheter drainage time was 3 days and the hospital stay time was 3 days. Conclusion The Toumai® minimally invasive endoscopic surgical robot is safe and effective in thoracic surgery. Compared with Da Vinci surgical robot, Toumai® has the same 3D visual field experience and smooth operation.
9.Sex differences in the efficacy of immune checkpoint inhibitors in treating patients with non-small cell lung cancer: A systematic review and meta-analysis
Xindong LUO ; Ziqiang HONG ; Baiqiang CUI ; Tao CHENG ; Yunjiu GOU
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2025;32(02):237-243
Objective To systematically review the sex differences in efficacy of immune checkpoint inhibitors (ICIs) for non-small cell lung cancer (NSCLC) patients. Methods We conducted a computer search of Medline, The Cochrane Library, and EMbase from inception to November 2022 to identify randomized controlled trials (RCTs) assessing the efficacy of ICIs in patients with NSCLC. A meta-analysis was performed using RevMan 5.4 software. Results Finally 16 RCTs with a total of 9 653 patients were included, and the modified Jadad scale score was≥4 points. Meta-analysis results showed that in female NSCLC patients receiving immune therapy, the median overall survival (OS) [HR=0.72, 95%CI (0.61, 0.85), P<0.001] was longer than that in males [HR=0.73, 95%CI (0.69, 0.78), P<0.001]. Males [HR=0.64, 95%CI (0.58, 0.71), P<0.001] had an advantage over females [HR=0.76, 95%CI (0.57, 1.03), P=0.760] in median progression-free survival (PFS). Conclusion Females receiving ICIs have an advantage over males in terms of median OS. However, males tend to derive greater benefit from ICIs in terms of median PFS.
10.Research progress of biomarkers for non-small cell lung cancer
Ziqiang HONG ; Dacheng JIN ; Xiangdou BAI ; Baiqiang CUI ; Yunjiu GOU
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2024;31(02):311-318
Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing efforts for its early detection by screening populations at risk, the majority of lung cancer patients are still diagnosed in an advanced stage. In the last decade, the treatment of non-small cell lung cancer (NSCLC) has been improved significantly. Emerging options of targeted therapies and immunotherapies have shifted the management of lung cancer to a more personalized treatment approach, significantly influencing the clinical course and outcome of the disease. At present, molecular biomarkers are becoming a powerful tool for diagnosing cancer, predicting treatment response outcomes, and assessing prognosis. In this review, we summarized the biomarkers relevant to the diagnosis, prediction, and prognosis of NSCLC as well as promising novel predictive biomarkers in the future.